PL3348556T3 - Heteroaryloamidy jako inhibitory agregacji białka - Google Patents

Heteroaryloamidy jako inhibitory agregacji białka

Info

Publication number
PL3348556T3
PL3348556T3 PL18156929T PL18156929T PL3348556T3 PL 3348556 T3 PL3348556 T3 PL 3348556T3 PL 18156929 T PL18156929 T PL 18156929T PL 18156929 T PL18156929 T PL 18156929T PL 3348556 T3 PL3348556 T3 PL 3348556T3
Authority
PL
Poland
Prior art keywords
inhibitors
protein aggregation
heteroaryl amides
heteroaryl
amides
Prior art date
Application number
PL18156929T
Other languages
English (en)
Polish (pl)
Inventor
Emily M. Stocking
Wolfgang Wrasidlo
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52484559&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3348556(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of PL3348556T3 publication Critical patent/PL3348556T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL18156929T 2014-01-29 2015-01-28 Heteroaryloamidy jako inhibitory agregacji białka PL3348556T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461933246P 2014-01-29 2014-01-29
US201462078895P 2014-11-12 2014-11-12
PCT/US2015/013263 WO2015116663A1 (en) 2014-01-29 2015-01-28 Heteroarly amides as inhibitors of protein aggregation
EP15705417.2A EP3099684B8 (en) 2014-01-29 2015-01-28 Heteroaryl amides as inhibitors of protein aggregation
EP18156929.4A EP3348556B1 (en) 2014-01-29 2015-01-28 Heteroaryl amides as inhibitors of protein aggregation

Publications (1)

Publication Number Publication Date
PL3348556T3 true PL3348556T3 (pl) 2020-11-02

Family

ID=52484559

Family Applications (2)

Application Number Title Priority Date Filing Date
PL18156929T PL3348556T3 (pl) 2014-01-29 2015-01-28 Heteroaryloamidy jako inhibitory agregacji białka
PL15705417T PL3099684T3 (pl) 2014-01-29 2015-01-28 Heteroaryloamidy jako inhibitory agregacji białka

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL15705417T PL3099684T3 (pl) 2014-01-29 2015-01-28 Heteroaryloamidy jako inhibitory agregacji białka

Country Status (38)

Country Link
US (3) US9738635B2 (enExample)
EP (2) EP3348556B1 (enExample)
JP (2) JP6619741B2 (enExample)
KR (1) KR102383038B1 (enExample)
CN (2) CN111039939B (enExample)
AP (1) AP2016009347A0 (enExample)
AU (1) AU2015211119B2 (enExample)
BR (2) BR112016017344B1 (enExample)
CA (1) CA2937967C (enExample)
CL (1) CL2016001918A1 (enExample)
CR (1) CR20160394A (enExample)
CY (2) CY1120348T1 (enExample)
DK (2) DK3348556T3 (enExample)
EA (1) EA032374B1 (enExample)
EC (1) ECSP16070327A (enExample)
ES (2) ES2675301T3 (enExample)
HK (1) HK1231470A1 (enExample)
HR (2) HRP20180813T1 (enExample)
HU (2) HUE040274T2 (enExample)
IL (1) IL246987B (enExample)
LT (2) LT3348556T (enExample)
ME (1) ME03800B (enExample)
MX (1) MX2016009896A (enExample)
MY (1) MY187450A (enExample)
NZ (1) NZ722487A (enExample)
PE (1) PE20161393A1 (enExample)
PH (1) PH12016501493B1 (enExample)
PL (2) PL3348556T3 (enExample)
PT (2) PT3099684T (enExample)
RS (2) RS60547B1 (enExample)
SA (1) SA516371579B1 (enExample)
SG (1) SG11201606108RA (enExample)
SI (2) SI3099684T1 (enExample)
SM (2) SMT202000376T1 (enExample)
TR (1) TR201809440T4 (enExample)
UA (1) UA118209C2 (enExample)
WO (1) WO2015116663A1 (enExample)
ZA (1) ZA201605246B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3348556T3 (da) 2014-01-29 2020-08-03 UCB Biopharma SRL Heteroarylamider som hæmmere af proteinaggregering
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
CN106474121B (zh) * 2016-11-25 2017-10-10 刘淑兰 一种治疗慢性盆腔炎的药物
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
BR112019011924A2 (pt) * 2017-01-26 2019-10-29 Ucb Biopharma Sprl derivados de bis-heteroarila bicíclicos como moduladores de agregação de proteína
JP7100042B2 (ja) * 2017-01-26 2022-07-12 ユーシービー バイオファルマ エスアールエル タンパク質凝集のモジュレーターとしてのアルコキシビス－ヘテロアリール誘導体
JP7100043B2 (ja) * 2017-01-26 2022-07-12 ユーシービー バイオファルマ エスアールエル タンパク質凝集のモジュレーターとしてのビス－ヘテロアリール誘導体
ES3035044T3 (en) * 2017-05-12 2025-08-27 Max Planck Gesellschaft Phenyl-heterocycle-phenyl derivatives for use in the treatment or prevention of melanoma
US11505528B2 (en) 2017-08-04 2022-11-22 Axial Therapeutics, Inc. Inhibitors of microbially induced amyloid
EP3703730A4 (en) * 2017-10-31 2022-01-12 Loma Linda University METHODS OF TREATMENT OF TRAUMATIC BRAIN LESIONS
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
WO2023125376A1 (zh) 2021-12-27 2023-07-06 上海京新生物医药有限公司 作为蛋白质聚集抑制剂的稠合双环杂芳基酰胺化合物
GB202213796D0 (en) * 2022-09-21 2022-11-02 Wista Lab Ltd Tau aggregation inhibitors
CN120265630A (zh) * 2022-11-02 2025-07-04 Ac免疫有限公司 用于诊断tdp-43蛋白质病的新化合物
WO2024184179A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2024184180A1 (en) 2023-03-06 2024-09-12 UCB Biopharma SRL Minzasolmin for use in the treatment of parkinson's disease
WO2025002040A1 (zh) * 2023-06-25 2025-01-02 上海京新生物医药有限公司 双环杂芳基酰胺化合物的晶型及盐、制备方法和用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997023202A1 (en) * 1995-12-22 1997-07-03 STATE OF OREGON, acting by and through THE OREGON STATE BOARD OF HIGHER EDUCATION, acting for and on behalf of THE OREGON HEALTH SCIENCES UNIVERSITYA ND THE UNIVERSITY OF OREGON, EUGENE OREGON Subtype-selective nmda receptor ligands and the use thereof
PL377795A1 (pl) * 2002-11-28 2006-02-20 Schering Aktiengesellschaft Pirymidyny będące inhibitorami Chk, Pdk i Akt, sposób ich wytwarzania oraz ich zastosowanie jako środków farmaceutycznych
CN101385722A (zh) * 2003-02-27 2009-03-18 乔安妮·麦克劳林 预防、治疗和诊断蛋白聚集疾病的方法
KR20070018824A (ko) * 2003-12-19 2007-02-14 브리스톨-마이어스 스큅 컴퍼니 카나비노이드 수용체 조절제인 아자비사이클릭헤테로사이클
US7816357B2 (en) * 2003-12-19 2010-10-19 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
TW200530246A (en) * 2003-12-19 2005-09-16 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
CN101023064B (zh) * 2004-08-26 2011-02-16 辉瑞大药厂 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物
US8106048B2 (en) * 2004-09-20 2012-01-31 4Sc Ag Heterocyclic NF-κB inhibitors
SE0403119D0 (sv) * 2004-12-21 2004-12-21 Astrazeneca Ab Therapeutic agents
WO2007006546A1 (en) 2005-07-11 2007-01-18 Devgen N.V. Amide derivatives as kinase inhibitors
JP2009502816A (ja) * 2005-07-29 2009-01-29 ４エスツェー アクチェンゲゼルシャフト 新規ヘテロ環状ＮＦ−κＢ阻害剤
CA2646223A1 (en) * 2006-03-15 2007-09-20 4Sc Ag Novel heterocyclic nf-kb inhibitors
CA2668744C (en) * 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
EP2155226A4 (en) * 2007-06-14 2010-07-28 Univ California COMPOUNDS FOR INHIBITING THE PROTEIN AGGREGATION AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2010068452A1 (en) * 2008-11-25 2010-06-17 Janssen Pharmaceutica Nv Heteroaryl-substituted urea modulators of fatty acid amide hydrolase
GB0910003D0 (en) * 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
WO2011048525A1 (en) 2009-10-20 2011-04-28 Pfizer Inc. Novel heteroaryl imidazoles and heteroaryl triazoles as gamma-secretase modulators
JP5922031B2 (ja) * 2009-12-16 2016-05-24 ニューロポア セラピーズ，インコーポレイティド 化合物
GB201021103D0 (en) 2010-12-13 2011-01-26 Univ Leuven Kath New compounds for the treatment of neurodegenerative diseases
WO2013134371A1 (en) 2012-03-06 2013-09-12 Neuropore Therapies, Inc. Methods and compounds to be used in the treatment of neurodegenerative diseases
US9527852B2 (en) 2012-03-28 2016-12-27 Neuropore Therapies, Inc. Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation
AU2013290361A1 (en) * 2012-07-16 2015-02-05 Neuropore Therapies, Inc. Di-and tri-heteroaryl derivatives as inhibitors of protein aggregation
DK3348556T3 (da) 2014-01-29 2020-08-03 UCB Biopharma SRL Heteroarylamider som hæmmere af proteinaggregering
US10975066B2 (en) 2015-07-29 2021-04-13 UCB Biopharma SRL Bis-heteroaryl derivatives as modulators of protein aggregation
BR112019011924A2 (pt) 2017-01-26 2019-10-29 Ucb Biopharma Sprl derivados de bis-heteroarila bicíclicos como moduladores de agregação de proteína
JP7100043B2 (ja) 2017-01-26 2022-07-12 ユーシービー バイオファルマ エスアールエル タンパク質凝集のモジュレーターとしてのビス－ヘテロアリール誘導体

Also Published As

Publication number Publication date
CA2937967A1 (en) 2015-08-06
JP6619741B2 (ja) 2019-12-11
US9738635B2 (en) 2017-08-22
EP3099684B8 (en) 2018-07-04
EA201691529A1 (ru) 2017-01-30
SMT201800318T1 (it) 2018-07-17
US10358443B2 (en) 2019-07-23
US20190308965A1 (en) 2019-10-10
EP3099684B1 (en) 2018-04-04
SMT202000376T1 (it) 2020-09-10
CN111039939B (zh) 2023-09-19
RS57533B1 (sr) 2018-10-31
EP3099684A1 (en) 2016-12-07
PT3099684T (pt) 2018-10-22
JP6783900B2 (ja) 2020-11-11
SI3099684T1 (en) 2018-08-31
TR201809440T4 (tr) 2018-07-23
MX2016009896A (es) 2017-01-11
CN106132960B (zh) 2019-12-17
AU2015211119A8 (en) 2016-12-15
US20160207912A1 (en) 2016-07-21
CY1120348T1 (el) 2019-07-10
SI3348556T1 (sl) 2020-10-30
DK3099684T3 (en) 2018-07-16
ME03800B (me) 2021-04-20
PH12016501493A1 (en) 2017-02-06
HUE050964T2 (hu) 2021-01-28
BR122018001892B1 (pt) 2023-05-02
PE20161393A1 (es) 2017-01-08
ES2808978T8 (es) 2021-03-22
ES2808978T3 (es) 2021-03-02
LT3348556T (lt) 2020-08-10
US20180093979A1 (en) 2018-04-05
SG11201606108RA (en) 2016-08-30
EP3348556B1 (en) 2020-04-29
AP2016009347A0 (en) 2016-07-31
CR20160394A (es) 2016-11-01
AU2015211119A1 (en) 2016-08-11
CA2937967C (en) 2022-07-26
ES2675301T3 (es) 2018-07-10
HRP20201107T8 (hr) 2020-12-11
HUE040274T2 (hu) 2019-03-28
ECSP16070327A (es) 2018-05-31
MY187450A (en) 2021-09-22
WO2015116663A8 (en) 2016-09-15
CY1123374T1 (el) 2021-12-31
PL3099684T3 (pl) 2018-09-28
IL246987A0 (en) 2016-09-29
CN111039939A (zh) 2020-04-21
KR20160113287A (ko) 2016-09-28
US11078196B2 (en) 2021-08-03
ZA201605246B (en) 2022-05-25
HK1231470A1 (zh) 2017-12-22
BR112016017344A2 (pt) 2017-10-03
BR112016017344B1 (pt) 2023-05-16
NZ722487A (en) 2022-04-29
SA516371579B1 (ar) 2019-07-16
EA032374B1 (ru) 2019-05-31
JP2019163321A (ja) 2019-09-26
AU2015211119B2 (en) 2019-05-30
KR102383038B1 (ko) 2022-04-05
JP2017505779A (ja) 2017-02-23
CL2016001918A1 (es) 2017-01-13
RS60547B1 (sr) 2020-08-31
PH12016501493B1 (en) 2017-02-06
HRP20180813T1 (hr) 2018-07-27
CN106132960A (zh) 2016-11-16
HRP20201107T1 (hr) 2020-10-30
LT3099684T (lt) 2018-06-25
DK3348556T3 (da) 2020-08-03
EP3348556A1 (en) 2018-07-18
PT3348556T (pt) 2020-07-27
IL246987B (en) 2021-12-01
UA118209C2 (uk) 2018-12-10
WO2015116663A1 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
HRP20201107T8 (hr) Heteroaril amidi kao inhibitori proteinske agregacije
ZA201702402B (en) Heteroaryl compounds as irak inhibitors and uses thereof
IL251584B (en) Dihydropyrrolopyridines ror–gamma inhibitors
IL246902A0 (en) Dihydropyrrolopyridine ror–gamma inhibitors
UA125061C2 (uk) Сполуки гетероарилу як інгібітори ткб і їх застосування
ZA201703867B (en) Synthesis of copanlisib and its dihydrochloride salt
ZA201703866B (en) Synthesis of copanlisib and its dihydrochloride salt
IL251568A0 (en) Aminopyridine substances are effective as prenylation inhibitors in proteins
GB201415425D0 (en) Small molecule inhibitors of classiv bromodomain proteins